News & Research
An emerging solution for people who are challenged by disconnection, which severely impacts their mental health, could be the resurgence of ancient plant medicines such as psilocybin.
Recent research from Imperial College and Kings College in London and Johns Hopkins in the US, are demonstrating that psilocybin along with other psychedelics have a valuable role in the treatment of mental health and combatting addictions, which will revolutionize psychiatry.
In 2018 the FDA granted psilocybin and MDMA the status of a 'breakthrough therapy'. The state of Oregon legalised psilocybin in November 2020 for use in a therapeutic setting which paves the way for other states to follow. This will usher in capital investment in psychedelic therapy and pharmacology to an estimated amount of $2bn over the next year.
Here in the UK, Imperial College and Kings College have seen amazing results from their trials and the first psychedelic-assisted psychotherapy clinic opens soon in Bristol.
Article by Carhart-Harris:
We can no longer ignore the potential of psychedelic drugs to treat depression
At Imperial College we’ve been comparing psilocybin to conventional antidepressants – and the results are likely to be game-changing.
The impact of successful psychedelic therapy is often one of revelation or epiphany. People speak of witnessing “the bigger picture”, placing things in perspective, accessing deep insight about themselves and the world, releasing pent-up mental pain, feeling emotionally and physically recalibrated, clear-sighted and equanimous.